MedTrace Logo

Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival

NCT03549351 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2022-09-13

No results posted yet for this study

Summary

Objectives To demonstrate that measurable residual disease assessed by multiparameter flow cytometry during intensive treatment is a surrogate for overall survival and thus an early read-out for drug efficacy Study design Surrogate endpoint trial to establish that measurable residual disease assessed by multiparameter flow cytometry during intensive treatment is a surrogate for overall survival

Conditions

  • Leukemia, Myeloid, Acute

Interventions

OTHER

Measurable residual disease measured by flow cytometry

Measurable residual disease measured by flow cytometry

Sponsors & Collaborators

  • University Hospital Dresden

    collaborator OTHER

  • German Cancer Research Center

    collaborator OTHER

  • University Hospital Heidelberg

    lead OTHER

Principal Investigators

  • Richard F Schlenk, Prof. Dr. · University Hospital Heidelberg

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2022-09-11
Completion
2022-09-11

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03549351 on ClinicalTrials.gov